| Experimental Factor Ontology (EFO) Information | |
| Identifier | EFO_0004341 |
| Description | Deposits of ADIPOSE TISSUE throughout the body. The pattern of fat deposits in the body regions is an indicator of health status. Excess ABDOMINAL FAT increases health risks more than excess fat around the hips or thighs, therefore, WAIST-HIP RATIO is often used to determine health risks. | Trait category |
Body measurement
|
| Synonym | body fat patterning |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS005233 (F2_Abdominal_Size) |
PGP000739 | Arehart CH et al. Nat Commun (2025) |
Abdominal size | body fat distribution | 710,487 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005233/ScoringFiles/PGS005233.txt.gz |
| PGS005234 (F3_Body_Size_and_Adipose_Distribution) |
PGP000739 | Arehart CH et al. Nat Commun (2025) |
Body size and adipose distribution | body weight, body fat distribution |
709,193 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005234/ScoringFiles/PGS005234.txt.gz |
| PGS005316 (BFM_PRS) |
PGP000766 | Türkmen D et al. Pharmacogenomics J (2024) |
Body fat mass | body fat distribution | 403 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005316/ScoringFiles/PGS005316.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM022665 | PGS005233 (F2_Abdominal_Size) |
PSS012051| European Ancestry| 100,960 individuals |
PGP000739 | Arehart CH et al. Nat Commun (2025) |
Reported Trait: Disorders of lipoid metabolism (phecode: 272) | OR: 1.1528 | — | — | age, sex, batch, and the first 10 genetic principal components | — |
| PPM022666 | PGS005234 (F3_Body_Size_and_Adipose_Distribution) |
PSS012051| European Ancestry| 100,960 individuals |
PGP000739 | Arehart CH et al. Nat Commun (2025) |
Reported Trait: Atrial fibrillation (phecode: 427.21) | OR: 1.16164 | — | — | age, sex, batch, and the first 10 genetic principal components | — |
| PPM023056 | PGS005316 (BFM_PRS) |
PSS012106| European Ancestry| 32,360 individuals |
PGP000766 | Türkmen D et al. Pharmacogenomics J (2024) |
Reported Trait: Incident heart failure | HR: 1.12 [1.07, 1.18] | — | — | sex, age at first prescription and genetic principal components 1 to 10 | — |
| PPM023057 | PGS005316 (BFM_PRS) |
PSS012106| European Ancestry| 32,360 individuals |
PGP000766 | Türkmen D et al. Pharmacogenomics J (2024) |
Reported Trait: Coronary heart disease | HR: 1.05 [1.02, 1.08] | — | — | sex, age at first prescription and genetic principal components 1 to 10 | — |
| PPM023058 | PGS005316 (BFM_PRS) |
PSS012106| European Ancestry| 32,360 individuals |
PGP000766 | Türkmen D et al. Pharmacogenomics J (2024) |
Reported Trait: Discontinuation of dCCB prescribing | HR: 1.04 [1.02, 1.06] | — | — | sex, age at first prescription and genetic principal components 1 to 10 | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS012051 | — | — | 25,240 individuals | — | European | — | CCPM | — |
| PSS012051 | — | — | 25,240 individuals | — | European | — | CCPM | — |
| PSS012051 | — | — | 25,240 individuals | — | European | — | CCPM | — |
| PSS012051 | — | — | 25,240 individuals | — | European | — | CCPM | — |
| PSS012106 | — | — | 32,360 individuals, 54.4 % Male samples |
— | European | — | UKB | — |